SEC Filings

8-K
AVEXIS, INC. filed this Form 8-K on 06/14/2017
Entire Document
 

 

Item 8.01.                                        Other Events.

 

On June 14, 2017, AveXis, Inc. (the “Registrant”) issued a press release announcing the Registrant’s alignment with the United States Food and Drug Administration (the “FDA”) on the Registrant’s Good Manufacturing Practice commercial manufacturing process for AVXS-101, the Registrant’s proprietary gene therapy, following the receipt of the minutes from the Registrant’s Type B Chemistry Manufacturing and Controls meeting with the FDA. The press release also announced information regarding a conference call to discuss this manufacturing update. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

 

 

Number

 

Exhibit Description

99.1

 

Press Release, dated June 14, 2017, titled “AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101.”

 

2



© AveXis, Inc. All Rights Reserved.